UroGen Pharma (URGN) PT Lowered to $21 at Oppenheimer on Slower Jelmyto Launch, Reiterates Outperform Rating, Sees Situation Improving in 2022 and Beyond
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| (NASDAQ: URGN) | Delayed: 34.49 -0.66 (1.88%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $35.15 | 52 Week High | $ | |||
| Open | $34.44 | 52 Week Low | $ | |||
| Day High | $35.02 | P/E | N/A | |||
| Day Low | $33.80 | EPS | $ | |||
| Volume | 738,097 | |||||
